RxDoctor Payments Data

Jane Iwebo

Psychiatric/Mental Health · Salisbury, MDNPI 1285296384

Payments from drug & device makers

$2,926in general payments, 2019–2025

Across 103 payments — averaging $28.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$995
  • Neurocrine Biosciences, Inc.$625
  • Otsuka America Pharmaceutical, Inc.$459
  • Vanda Pharmaceuticals Inc.$448
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$95
  • Johnson & Johnson$69
  • plus $236 from 6 others

What the payments were for

  • Food & beverage$2,926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,926 in reported general payments places this provider in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$75,894
Medicare patients
83
Services billed
738

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$23,039
Aripiprazole139$3,630
Doxepin Hcl73$2,835
Duloxetine Hcl156$2,031
Bupropion XlBupropion Hcl111$1,718
Mirtazapine72$1,497
Sertraline Hcl175$1,334
Buspirone Hcl199$1,093
Escitalopram Oxalate131$994
Trazodone Hcl210$970
Quetiapine Fumarate79$877
Olanzapine43$691
Hydroxyzine Hcl112$681
Divalproex Sodium ErDivalproex Sodium17$659
Bupropion Hcl64$647

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$995$23,03918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →